Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Mai 2025 09:00 ET | Quelle: BIOXYTRAN, INC.

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced...
21. Februar 2024 08:00 ET | Quelle: BIOXYTRAN, INC.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
25. September 2023 14:40 ET | Quelle: Zion Market Research

Radiation Dose Management Market Size Will Attain USD 7.77 Billion by 2030 Registering a Promising CAGR of 4.79% - Exclusive Report by Zion Market Research

NEW YORK, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Radiation Dose Management Market By Modality (Computed Tomography,...